GRAIL.
American biotechnology and pharmaceutical company
- Reports this week
- 2
- Active events
- 2
- Connections
- 79
What's happening
Active this week
Earlier this month
-
The FDA is evaluating GRAIL's Galleri test as a breakthrough device, with Medicare coverage depending on the thorough FDA vetting.Well supported5 reports3 developments inside
-
FDA voted in favor of the safety and effectiveness of GRAIL's Galleri blood test.Some support1 report
-
GRAIL is pursuing commercialization and expansion of its Galleri test into Asian markets, including a collaboration in South Korea.Some support2 reports
-
GRAIL and Guardant Health, both companies specializing in cancer detection blood tests, are trading on the Nasdaq stock exchange.Some support1 report
-
GRAIL and Gilead Sciences, both healthcare companies, are competing for investment.Some support1 report
-
CVS Health's Caremark profit depends on drug payment gaps, while GRAIL awaits FDA approval until 2027, and Jim Cramer called CVS Health cheap.Some support1 report
-
Jim Cramer predicted that shares of Grail will rise.Some support1 report
-
A lawsuit was filed against GRAIL in the Northern District of California.Well supported13 reports
-
A lawsuit was filed in New York City involving the company GRAIL.Well supported18 reports4 developments inside
-
GRAIL disclosed insider transactions via SEC filing while its stock traded on the Nasdaq exchange on June 5, 2026.Well supported6 reports
-
A study conducted at Mayo Clinic on September 24 validated the efficacy of Grail's multi-cancer early detection test.Some support1 report
-
Grail is conducting trials with the NHS, seeking FDA approval for its Galleri test, and presenting data at ASCO.Well supported5 reports
-
A key meeting was held to review the Galleri blood test developed by GRAIL.Some support1 report
One to three months ago
-
GRAIL and Exelixis, both healthcare companies, are competing for investment.Some support1 report
-
GRAIL and Kalaris Therapeutics are competing for market share in the healthcare sector.Some support1 report
-
GRAIL utilizes a central laboratory in North Carolina and leverages Quest locations for blood sample collection for its multi-cancer early detection test.Some support1 report
-
The company GRAIL is based in New York.Some support1 report
Gone quiet
No new reports in 90+ days-
Due to trial failure, GRAIL's stock price has plummeted by over 50%.Some support2 reports
-
An investor rights law firm reminds purchasers regarding the class action lawsuit against GRAIL.Well supported4 reports
-
GRAIL conducted an NHS-Galleri trial and a class action lawsuit was filed in the Northern District.Some support4 reports
-
GRAIL common stock purchasers are being notified in New York.Some support1 report
-
Phillip Kim was contacted regarding the ongoing class action lawsuit against GRAIL.Some support2 reports
-
GRAIL filed reports with the SEC on June 18, 2026.Some support1 report
-
Grail was formed following a spin-off from Illumina, and Morgan Stanley reiterated its 'Equal Weight' stance on the companies.Speculative3 reports
-
Renee Gala, a former executive at GRAIL, was noted on July 11, 2025.Some support1 report
-
Galleri is the multi-cancer early detection test developed by GRAIL.Some support1 report
-
Dynatrace announced results from Boston, revealing that its platform is powered by GRAIL and led by CEO Rick McConnell.Some support4 reports
-
GRAIL reported an impairment of assets related to its acquisition of Illumina.Some support2 reports
-
GRAIL is headquartered in Menlo Park, CA.Some support4 reports
No events began in the chosen period. Widen it, or reset.
Explainers that pass through GRAIL
GRAIL is a step on the way to someone elseAround GRAIL this week
News at the entities that move GRAIL most-
FDA StructuralAbbott Laboratories faces an FDA recall classification of its sensors, while Ken Fisher and Donald Trump engage in stock transactions.Moves GRAIL
-
Illumina StructuralDirector Keith Meister sold shares of Illumina stock on October 15, 2026.Moves GRAIL
-
SEC StructuralThe SEC has mandated that filings regarding ETF holdings must be submitted.Moves GRAIL
-
New York StructuralLawmakers, including Clarke and Thanedar, led an appeal regarding healthcare access after an Arizona woman lost Medicaid coverage.Moves GRAIL
-
Medicare StructuralAmy Gleason leads the CMS Health Tech Ecosystem program.Moves GRAIL
-
Tricare OperationalHHS granted CMS power to bar providers from Medicare and Tricare, and CMS ran an AI fraud test pilot in Indiana.Moves GRAIL
Connections
The 40 strongest of 79, analyzed from the reporting. The bars show how strongly a change on one side reaches the other.-
Illumina Structural
GRAIL maintains a structural financial relationship with Illumina as its largest shareholder and through ongoing royalty obligations.
-
FDA Structural
GRAIL's commercial viability and product adoption are structurally dependent on receiving regulatory approval from the FDA.
-
Partridge Structural
Partridge holds the role of Chief Growth Officer at GRAIL.
-
SEC Structural
GRAIL operates under mandatory regulatory oversight by the SEC regarding financial disclosures and insider trading.
-
athenahealth Structural
GRAIL integrates its test ordering into athenahealth's platform, establishing a partnership for test distribution.
-
Food and Drug Administration Structural
Grail seeks market approval for its Galleri product from the Food and Drug Administration (FDA).
-
National Health Service Transactional
GRAIL is conducting a clinical trial with the NHS for the implementation of the Galleri test.
-
Canyon Structural
The product line associated with GRAIL utilizes Canyon as the manufacturer and developer of the Grail bike series.
Show all 40 connections
-
Dynatrace Structural
Grail provides the core data lakehouse foundation and architecture for Dynatrace's AI platform.
-
Medicare Structural
GRAIL's market access and revenue generation depend structurally on Medicare's reimbursement decisions following FDA vetting.
-
Tricare Operational
Tricare's coverage decisions enable GRAIL's diagnostic tests to gain market accessibility and expand its addressable population.
-
Quest Diagnostics Operational
GRAIL integrates its diagnostic tests into Quest's collection and testing network, leveraging Quest's infrastructure for service delivery.
-
New York Structural
GRAIL is subject to legal and regulatory actions and is based within the jurisdiction of New York.
-
National Health Service Structural
GRAIL's products are undergoing performance testing and validation within the operational framework of the National Health Service.
-
IBM Operational
GRAIL mission data is integrated into the foundation model utilized by IBM.
-
Northern District Transactional
GRAIL is involved in a class action lawsuit pending in the Northern District Court.
-
Samsung Electronics Transactional
Samsung Electronics made an investment in GRAIL.
-
Megan Hall Structural
Megan Hall serves as the VP of medical affairs for Grail.
-
Samsung C&T Transactional
Samsung C&T invested in GRAIL.
-
Shimano Structural
Grail bikes rely on Shimano drivetrains as a functional component, establishing a supply chain dependency.
-
Morgan Stanley Mentioned together
Morgan Stanley provides financial analysis and target price recommendations regarding GRAIL.
-
Robbins Geller Rudman & Dowd LLP Transactional
The law firm is leading a class action lawsuit against the company.
-
Royal Bank of Canada Mentioned together
Royal Bank of Canada has begun providing financial coverage and analysis of GRAIL stock.
-
American Society of Clinical Oncology Operational
Grail presented clinical data at the American Society of Clinical Oncology annual meeting to strengthen its scientific case.
-
Exelixis Operational
Both companies are healthcare entities that compete for investment in the market.
-
WHOOP Operational
WHOOP provides access to GRAIL's multi-cancer early detection test.
-
Mayo Clinic Operational
Mayo Clinic conducted a study that validated the efficacy of Grail's test.
-
Jim Cramer Operational
Jim Cramer actively provides stock commentary and predictions regarding GRAIL's shares.
-
Los Angeles Shared context
GRAIL's legal challenges are tied to a law firm office situated in Los Angeles.
-
Josh Wilson Transactional
Josh Wilson represents investors in securities litigation concerning Grail.
-
Nvidia Mentioned together
Nvidia is referenced as a size comparison point for GRAIL.
-
Nasdaq Shared context
GRAIL's stock is listed and traded on the Nasdaq exchange.
-
TD Cowen Mentioned together
TD Cowen provides investment ratings and price targets for GRAIL shares.
-
North Carolina Shared context
GRAIL's central laboratory is located in North Carolina.
-
New York Shared context
A lawsuit announcement involving GRAIL was observed to originate in New York.
-
Mizuho Mentioned together
Mizuho raised its price target for GRAIL, indicating market assessment of A by B.
-
England Shared context
Grail conducted a clinical trial within the geographical and regulatory context of England.
-
Guardant Health Operational
Both GRAIL and Guardant Health actively compete in the market by selling blood tests for cancer detection.
-
S&P Global Market Intelligence Mentioned together
S&P Global Market Intelligence tracks and reports on GRAIL's stock performance.
-
New York City Shared context
GRAIL is involved in a class action lawsuit that is being processed in New York City.
History
Events by the month they beganOctober 2026
5 events- FDA voted in favor of the safety and effectiveness of GRAIL's Galleri blood test.
- GRAIL and Guardant Health, both companies specializing in cancer detection blood tests, are trading on the Nasdaq stock exchange.
- GRAIL and Gilead Sciences, both healthcare companies, are competing for investment.
- CVS Health's Caremark profit depends on drug payment gaps, while GRAIL awaits FDA approval until 2027, and Jim Cramer called CVS Health cheap.
- Jim Cramer predicted that shares of Grail will rise.
September 2026
4 events- A study conducted at Mayo Clinic on September 24 validated the efficacy of Grail's multi-cancer early detection test.
- A key meeting was held to review the Galleri blood test developed by GRAIL.
- GRAIL and Exelixis, both healthcare companies, are competing for investment.
- GRAIL and Kalaris Therapeutics are competing for market share in the healthcare sector.
August 2026
4 events- TD Cowen provided a buy rating on GRAIL shares on August 6, 2026.
- GRAIL is pursuing commercialization and expansion of its Galleri test into Asian markets, including a collaboration in South Korea.
- GRAIL utilizes a central laboratory in North Carolina and leverages Quest locations for blood sample collection for its multi-cancer early detection test.
- The company GRAIL is based in New York.
Show 1 earlier month
June 2026
18 events- FSK is involved in a class action lawsuit, represented by Robbins Geller Rudman & Dowd LLP.
- The FDA is evaluating GRAIL's Galleri test as a breakthrough device, with Medicare coverage depending on the thorough FDA vetting.
- A lawsuit was filed against GRAIL in the Northern District of California.
- A lawsuit was filed in New York City involving the company GRAIL.
- GRAIL disclosed insider transactions via SEC filing while its stock traded on the Nasdaq exchange on June 5, 2026.
- Grail is conducting trials with the NHS, seeking FDA approval for its Galleri test, and presenting data at ASCO.
- Due to trial failure, GRAIL's stock price has plummeted by over 50%.
- An investor rights law firm reminds purchasers regarding the class action lawsuit against GRAIL.
- GRAIL conducted an NHS-Galleri trial and a class action lawsuit was filed in the Northern District.
- GRAIL common stock purchasers are being notified in New York.
- Phillip Kim was contacted regarding the ongoing class action lawsuit against GRAIL.
- GRAIL filed reports with the SEC on June 18, 2026.
- Grail was formed following a spin-off from Illumina, and Morgan Stanley reiterated its 'Equal Weight' stance on the companies.
- Renee Gala, a former executive at GRAIL, was noted on July 11, 2025.
- Galleri is the multi-cancer early detection test developed by GRAIL.
- Dynatrace announced results from Boston, revealing that its platform is powered by GRAIL and led by CEO Rick McConnell.
- GRAIL reported an impairment of assets related to its acquisition of Illumina.
- GRAIL is headquartered in Menlo Park, CA.